Global MASLD Prevalence Skyrockets: 1.3 Billion Cases in 2023, 143% Increase Since 1990
A groundbreaking study published in The Lancet Gastroenterology and Hepatology journal has revealed alarming statistics about Metabolic dysfunction-associated steatotic liver disease (MASLD), estimating that approximately 1.3 billion people worldwide were living with the condition in 2023. This figure represents a staggering 143 per cent increase since 1990, highlighting a rapidly escalating global health crisis.
Projections Point to 1.8 Billion Cases by 2050
The analysis, which draws on comprehensive data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023, projects that global MASLD cases could soar to about 1.8 billion by 2050. This dramatic rise is primarily driven by population growth and significant lifestyle changes, including increasing rates of obesity and high blood sugar levels across many regions.
Regional Disparities and Demographic Shifts
Researchers from the GBD 2023 MASLD Collaborators identified notable regional disparities, with areas such as North Africa and the Middle East experiencing disproportionately higher rates of MASLD compared to other parts of the world. Furthermore, the study underscores that MASLD is increasingly affecting younger adults in low- and middle-income countries, a trend linked to ongoing urbanisation and shifts in dietary and physical activity patterns.
Health Impact and Treatment Advances
Despite the sharp increase in case numbers, the overall health impact of MASLD—measured in years lost due to illness or premature death—has remained relatively stable. This stability suggests that advances in medical treatment and care are enabling individuals to live longer and healthier lives with the disease. The researchers noted that much of the increase in cases is occurring in the early stages of MASLD, which may be more manageable with timely intervention.
Risks of Future Complications
However, the growing prevalence of MASLD still poses significant risks, as many affected individuals are at heightened risk of developing serious complications in the future, including liver cirrhosis or cancer. The study's authors emphasize that the sheer number of cases means a substantial portion of the global population could face these severe health outcomes if preventive measures are not implemented.
Call for Global Health Priority
The findings strongly advocate for recognizing MASLD as a global health priority. The research team calls for the development of dedicated policies, widespread awareness campaigns, and targeted interventions to mitigate the growing impact of the disease and prevent future complications. In their published statement, the authors detailed: "In 2023, approximately 1.3 billion individuals were estimated to be living with MASLD (ie, 16.1 per cent of the global population), with an age-standardised prevalence rate of 14,429.3 per 1,00,000 population, representing a percentage increase of 142.7 per cent in crude numbers from 1990 and of 28.6 per cent in the rate (11,217.2 per 1,00,000 in 1990)."
This comprehensive study serves as a critical wake-up call for health authorities worldwide, urging immediate action to address the escalating burden of metabolic liver disease through improved public health strategies and enhanced medical care.
